Serum ischemia-modified albumin in patients with type 2 diabetes mellitus with and without diabetic nephropathy: A cross-sectional study
4 affiliations
- 1Department of Anatomy, All India Institute of Medical Sciences (AIIMS), MIHAN, Dahegaon, Maharashtra 441108, India
- 2Department of Medicine, All India Institute of Medical Sciences (AIIMS), MIHAN, Dahegaon, Maharashtra 441108, India
- 3Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), MIHAN, Dahegaon, Maharashtra 441108, India
- 4Department of Laboratory Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, Delhi 110029, India
Abstract
Diabetic nephropathy is the leading cause of end-stage renal disease worldwide, and ischemia-modified albumin (IMA) has been proposed as a biomarker of oxidative stress in type 2 diabetes mellitus (T2DM). The present hospital-based cross-sectional study evaluated serum IMA levels together with biochemical, haematological, urinary and comorbidity profiles in patients with T2DM with and without nephropathy. The primary outcome was the between-group difference in serum IMA; there was no healthy control group. A total of 50 patients were enrolled between November, 2021 and March, 2024, including 25 patients with T2DM without nephropathy (group A) and 25 patients with diabetic nephropathy (group B). Clinical and laboratory records were available for 19 patients in group A and 16 patients in group B; the others contributed IMA values only. In group B, chronic kidney disease (CKD) stage 5D was documented in 9 patients, CKD on maintenance haemodialysis in 1 patient, acute-on-chronic kidney disease in 1 patient, CKD of unspecified stage in 4 patients, and 10 patients had no clinical record. Serum IMA levels did not differ significantly between the groups [group A: Median, 0.332 absorbance units (ABSU); group B: Median, 0.317 ABSU; Mann-Whitney test; P=0.727; mean difference (group A vs. B), 0.054 ABSU, 95% confidence interval, -0.08 to 0.19]; thus, a clinically relevant difference cannot be excluded. The result was similar following adjustment for serum albumin and in sensitivity analyses (all P>0.5). Blood urea (P=0.0003) and serum creatinine (P<0.0001) levels were higher in group B; the serum potassium level was nominally higher (P=0.040), but within the normal range in both groups. Among the patients with records, anaemia (14/18, 78% vs. 10/15, 67%) and infection (12/18, 67% vs. 9/15, 60%) were more frequent in group A than in group B. Heavy proteinuria (+++/++++) was recorded only in group B (2/7 tested) and all adverse in-hospital outcomes occurred in group B; however, these comparisons rest on very small numbers. In the present small study without a healthy control group, serum IMA did not differ between patients with T2DM with and without nephropathy, and the findings are compatible with IMA reflecting systemic oxidative stress rather than nephropathy-specific injury. Larger prospective studies with standardized IMA assays, albumin adjustment and comprehensive biochemical profiling are required to clarify the clinical utility of IMA in diabetic kidney disease.
Related
- Dose-Dependent Association of Long-Term Metformin Use and Diabetic Nephropathy Risk in Patients with Type 2 Diabetes Mellitus: A Nationwide Population-Based Study in Taiwan
- Orthoplastic Limb Salvage Using Transtibial Transport and Free-Flap Reconstruction in Patients With Diabetes-Related Chronic Limb-Threatening Ischemia
- Pre-diabetes and diabetes among young first-degree relatives of patients with type 2 diabetes: prevalence and associated factors in a cross-sectional study in Dar-es-Salaam, Tanzania
- Factors associated with chronic kidney disease stage among patients with uncontrolled diabetes and/or hypertension in Northeastern Thailand: a cross-sectional study
- Association of salivary function with oral health-related quality of life in patients with type 2 diabetes and xerostomia: cross-sectional study
BibTeX
@article{sontakke2026serum,
title = {{Serum ischemia-modified albumin in patients with type 2 diabetes mellitus with and without diabetic nephropathy: A cross-sectional study}},
author = {Bharat Ramrao Sontakke and Vishwajit Deshmukh and Bharat Singh Rathod and Jancy Jose and Satyendra Tripathi and Yash Bisht and Ashok Kumar Ahirwar},
journal = {Medicine International},
year = {2026},
month = oct,
doi = {10.3892/mi.2026.346},
url = {https://doi.org/10.3892/mi.2026.346},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Serum ischemia-modified albumin in patients with type 2 diabetes mellitus with and without diabetic nephropathy: A cross-sectional study
AU - Bharat Ramrao Sontakke
AU - Vishwajit Deshmukh
AU - Bharat Singh Rathod
AU - Jancy Jose
AU - Satyendra Tripathi
AU - Yash Bisht
AU - Ashok Kumar Ahirwar
PY - 2026
DA - 2026/10/23
JO - Medicine International
DO - 10.3892/mi.2026.346
UR - https://doi.org/10.3892/mi.2026.346
AB - Diabetic nephropathy is the leading cause of end-stage renal disease worldwide, and ischemia-modified albumin (IMA) has been proposed as a biomarker of oxidative stress in type 2 diabetes mellitus (T2DM). The present hospital-based cross-sectional study evaluated serum IMA levels together with biochemical, haematological, urinary and comorbidity profiles in patients with T2DM with and without nephropathy. The primary outcome was the between-group difference in serum IMA; there was no healthy control group. A total of 50 patients were enrolled between November, 2021 and March, 2024, including 25 patients with T2DM without nephropathy (group A) and 25 patients with diabetic nephropathy (group B). Clinical and laboratory records were available for 19 patients in group A and 16 patients in group B; the others contributed IMA values only. In group B, chronic kidney disease (CKD) stage 5D was documented in 9 patients, CKD on maintenance haemodialysis in 1 patient, acute-on-chronic kidney disease in 1 patient, CKD of unspecified stage in 4 patients, and 10 patients had no clinical record. Serum IMA levels did not differ significantly between the groups [group A: Median, 0.332 absorbance units (ABSU); group B: Median, 0.317 ABSU; Mann-Whitney test; P=0.727; mean difference (group A vs. B), 0.054 ABSU, 95% confidence interval, -0.08 to 0.19]; thus, a clinically relevant difference cannot be excluded. The result was similar following adjustment for serum albumin and in sensitivity analyses (all P>0.5). Blood urea (P=0.0003) and serum creatinine (P<0.0001) levels were higher in group B; the serum potassium level was nominally higher (P=0.040), but within the normal range in both groups. Among the patients with records, anaemia (14/18, 78% vs. 10/15, 67%) and infection (12/18, 67% vs. 9/15, 60%) were more frequent in group A than in group B. Heavy proteinuria (+++/++++) was recorded only in group B (2/7 tested) and all adverse in-hospital outcomes occurred in group B; however, these comparisons rest on very small numbers. In the present small study without a healthy control group, serum IMA did not differ between patients with T2DM with and without nephropathy, and the findings are compatible with IMA reflecting systemic oxidative stress rather than nephropathy-specific injury. Larger prospective studies with standardized IMA assays, albumin adjustment and comprehensive biochemical profiling are required to clarify the clinical utility of IMA in diabetic kidney disease.
SN - 2754-3242
SN - 2754-1304
ER -